Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01400555 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 1 study, sponsored by Cougar Biotechnology.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01400555 is a Phase 1 study that has completed, run by Cougar Biotechnology. The registered enrollment target is 22 participants.
The verdict
NCT01400555, a Phase 1 study, has completed, sponsored by Cougar Biotechnology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the maximum safe dose of abiraterone acetate administered in combination with docetaxel plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
Interventions
- DRUG Cohort 4
- DRUG Cohort 3
- DRUG Cohort 2
- DRUG Cohort 1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2011-09-01 |
| Est. Completion | 2017-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01400555
The ClinicalTrials.gov registry entry for NCT01400555 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cougar Biotechnology, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cohort 4 is the first listed.
NCT01400555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01400555 about?
NCT01400555 is a clinical study titled "A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)". The purpose of this study is to evaluate the maximum safe dose of abiraterone acetate administered in combination with docetaxel plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
What is the current status of trial NCT01400555?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2011-09-01. Estimated completion is 2017-02-28.
What interventions are being tested in trial NCT01400555?
The interventions under investigation include: Cohort 4 (DRUG), Cohort 3 (DRUG), Cohort 2 (DRUG), Cohort 1 (DRUG).
Who is sponsoring clinical trial NCT01400555?
This trial is sponsored by Cougar Biotechnology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.